{
    "2021-08-10": [
        [
            {
                "time": "2021-08-30",
                "original_text": "东吴证券维持贝达药业买入评级，2021年中报点评：业绩符合我们的预期，凯美纳+贝美纳双驱动，持续巩固非小细胞肺癌领域优势",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯美纳",
                        "贝美纳",
                        "非小细胞肺癌",
                        "双驱动"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "华西证券维持贝达药业买入评级：业绩符合预期，新产品快速拓展市场",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "新产品",
                        "市场拓展"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "贝达药业第四代EGFR抑制剂BPI-361175项目I期临床研究首例受试者入组",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "EGFR抑制剂",
                        "BPI-361175",
                        "临床研究"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "华鑫证券维持贝达药业推荐评级：业绩符合预期，研发稳步推进",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "研发",
                        "推进"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "天风证券维持贝达药业增持评级：业绩增长符合预期，肺癌领域多款药物取得进展",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "肺癌",
                        "药物进展"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "国盛证券维持贝达药业买入评级：上半年表现亮眼，收获颇丰，Q2实现高速增长",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "上半年",
                        "Q2",
                        "高速增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "凯美纳持续放量 贝达药业上半年净利润超2亿",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯美纳",
                        "净利润",
                        "放量"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "贝达药业2021H1净利润同比增长近50%，凯美纳十年累计销售收入超100亿",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "凯美纳",
                        "净利润",
                        "同比增长"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "中泰证券维持贝达药业买入评级：业绩符合预期，EGFR、ALK抑制剂双轮驱动主业强劲增长",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "EGFR",
                        "ALK",
                        "抑制剂",
                        "双轮驱动"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "东莞证券维持贝达药业推荐评级，2021年中报点评：Q2业绩实现快增，研发持续推进",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "Q2",
                        "业绩快增",
                        "研发"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-30",
                "original_text": "贝达药业：中期盈利2.15亿人民币，同比增长49.57%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "中期盈利",
                        "同比增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}